KPV (Lys-Pro-Val) — Anti-Inflammatory Tripeptide | α-MSH Fragment Research

This article is for informational and educational purposes only and does not constitute medical advice. KPV is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.

Research Summary

KPV is a synthetic tripeptide with the sequence Lys-Pro-Val and a molecular weight of approximately 342 Da. It corresponds to residues 11–13 of α-melanocyte-stimulating hormone (α-MSH), the tridecapeptide derived from pro-opiomelanocortin (POMC) with established roles in pigmentation, energy homeostasis, and anti-inflammatory signaling. Research interest in KPV centers primarily on its anti-inflammatory properties: independent preclinical studies have reported NF-κB pathway inhibition in intestinal epithelial cells and macrophage preparations, suppression of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β, and protective effects in rodent models of experimental colitis. KPV is proposed to partly retain the receptor engagement properties of full-length α-MSH, particularly at melanocortin receptor 1 (MC1R), though with substantially lower affinity than the parent peptide. Unlike some research compounds studied predominantly by a single laboratory group, KPV’s anti-inflammatory activity in cell culture models has been reported by multiple independent research teams. Controlled human clinical data remain absent, pharmacokinetics are not well characterized, and no regulatory authority has approved KPV for any clinical indication.

1. Background

1.1 α-MSH and the Melanocortin System

α-Melanocyte-stimulating hormone (α-MSH) is a 13-amino-acid peptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) derived from pro-opiomelanocortin (POMC) through post-translational proteolytic processing. It is produced by melanotrophs in the pituitary intermediate lobe, by neurons in the arcuate nucleus of the hypothalamus, and by peripheral cell types including keratinocytes, macrophages, and dermal fibroblasts. α-MSH is a ligand for melanocortin receptors (MC1R through MC5R), a family of G protein-coupled receptors. MC1R, expressed on melanocytes, immune cells, and keratinocytes, mediates both the pigmentation response and anti-inflammatory signaling; it is also the pharmacological target of Melanotan I and Melanotan II. MC3R and MC4R are expressed centrally and regulate energy homeostasis and feeding behavior, while MC2R is the primary ACTH receptor in the adrenal cortex.

The anti-inflammatory properties of α-MSH have been documented since the 1990s through the work of James Lipton, Anna Catania, and colleagues, who demonstrated that α-MSH and its fragments reduce fever, inhibit pro-inflammatory cytokine production, and protect against inflammatory tissue damage in animal models [2]. The finding that the C-terminal tripeptide KPV retained significant anti-inflammatory activity despite lacking the N-terminal acetylation and C-terminal amidation of native α-MSH established it as what is widely regarded as the minimal fragment reported to retain measurable anti-inflammatory activity in experimental models.

1.2 The KPV Fragment: Structure-Activity Relationship Context

The importance of the C-terminal sequence to α-MSH’s anti-inflammatory activity was established through systematic truncation studies. Progressively shorter C-terminal fragments of α-MSH show a clear reduction in anti-inflammatory potency, with KPV identified as the minimal sequence retaining detectable activity in standard cytokine suppression assays [1]. The lysine residue at position 1 of KPV appears critical: substitution with a neutral residue substantially reduces anti-inflammatory potency, consistent with the basic side chain’s role in receptor binding or electrostatic interactions relevant to the mechanism. This structure-activity relationship positions KPV as a pharmacologically relevant fragment rather than a simple proteolytic degradation product.

KPV is incorporated as a component in the Klow research blend, where its proposed NF-κB inhibition is hypothesized to reduce inflammatory-driven MMP upregulation and ECM catabolism in a tissue matrix remodeling research context.

2. Molecular Structure

Lys

–

Pro

–

Val

Basic (Lys)

Non-polar/neutral (Pro, Val)

Table 1 — KPV Structural Properties
Property	Value
Full name	KPV (Lys-Pro-Val)
Sequence (single-letter)	KPV
Sequence (full names)	Lys-Pro-Val
Molecular weight	~342 Da
Molecular formula	C₁₆H₃₀N₄O₄
Peptide length	3 amino acids (tripeptide)
Net charge (physiological pH)	+1 (Lys ε-amino group +1 at pH 7.4; Pro and Val neutral; no acidic side chains)
Origin	Synthetic; corresponds to residues 11–13 of α-melanocyte-stimulating hormone (α-MSH)
Proposed primary targets	MC1R (melanocortin receptor 1); NF-κB signaling pathway; inflammatory cell cytokine production
Parent peptide	α-MSH (13 residues; Ac-SYSMEHFRWGKVP-NH₂); KPV = residues 11–13

KPV carries a net charge of +1 at physiological pH — the only positively charged compound among the melanocortin fragment entries in this catalog, and notably distinct from the doubly negative EDP sequence of Crystagen. Proline at position 2 constrains backbone conformation, while valine at position 3 contributes hydrophobic character at the C-terminus, a property noted as relevant to receptor binding in SAR studies of α-MSH C-terminal fragments.

3. Proposed Mechanisms of Action

Note: The proposed mechanisms below are based on in vitro cell culture experiments and animal studies. While KPV’s anti-inflammatory effects in cell culture have been reported by multiple independent research groups, the precise molecular mechanism linking KPV to each downstream effect has not been fully resolved, and no human clinical data are available to validate these pathways in vivo.

Primary Mechanism

NF-κB Pathway Inhibition

The primary proposed mechanism of KPV is inhibition of NF-κB signaling, a master regulator of pro-inflammatory gene expression. In intestinal epithelial cell and macrophage models, KPV treatment has been associated with reduced nuclear translocation of NF-κB subunits and attenuated expression of downstream inflammatory mediators including TNF-α, IL-6, IL-1β, and IL-8. The upstream event linking KPV to NF-κB suppression — whether through receptor-mediated cAMP elevation, direct IKK complex interaction, or another route — has not been definitively characterized across all experimental systems.

Receptor Engagement

MC1R Activity

As a C-terminal fragment of α-MSH, KPV is proposed to retain partial capacity to engage melanocortin receptors, with proposed preferential activity at MC1R. MC1R activation by α-MSH and its analogs is linked to anti-inflammatory signaling through cAMP-dependent protein kinase A (PKA) activation, which can suppress NF-κB and MAPK-driven inflammatory pathways. KPV’s affinity for MC1R is substantially lower than that of full-length α-MSH and may be insufficient for appreciable receptor occupancy at physiologically plausible concentrations. Whether KPV’s observed anti-inflammatory effects are primarily MC1R-mediated or operate through receptor-independent intracellular mechanisms remains unresolved.

Gut Epithelial Context

Intestinal Barrier and Mucosal Protection

A significant body of KPV preclinical research has examined effects in intestinal epithelial cell systems relevant to inflammatory bowel disease (IBD). Studies have reported that KPV treatment is associated with maintenance of epithelial barrier integrity, reduced intestinal permeability indices under inflammatory challenge, and protection of tight junction protein expression. Interest in oral delivery of KPV to inflamed colonic epithelium has driven development of nanoparticle and hydrogel formulations designed to protect the tripeptide from proteolytic degradation in the gastrointestinal lumen and enable mucosal targeting.

Immune Cell Effects

Cytokine Modulation in Macrophages

Beyond gut epithelial contexts, KPV has been studied in macrophage and monocyte cell preparations. In these systems, KPV has been reported to modulate cytokine production profiles following LPS or TNF-α stimulation, with consistent reductions in TNF-α and IL-6 secretion. Macrophages and monocytes express MC1R and MC3R, providing a plausible receptor basis for melanocortin-mediated anti-inflammatory signaling in these cell types. The relative contribution of receptor-mediated versus receptor-independent mechanisms to cytokine modulation by KPV in macrophages has not been definitively resolved.

4. Key Research Findings

4.1 In Vitro Cell Culture Studies

The in vitro evidence base for KPV is broader than for many research peptides with single-group origin, with studies reported from multiple independent laboratories using intestinal epithelial cell lines (Caco-2, HT-29, T84), macrophage models (RAW 264.7, THP-1, primary peritoneal macrophages), and primary human immune cell preparations. Across these systems, KPV treatment has been consistently associated with reduced NF-κB activation and attenuation of pro-inflammatory cytokine production following stimulation with LPS, TNF-α, or other inflammatory triggers [1,2]. The convergence of anti-inflammatory observations across independent laboratories using different cell models provides stronger support for KPV’s anti-inflammatory cell culture activity than is typical for compounds investigated by a single research group.

Preclinical Data Only: All findings below are from cell culture experiments and animal models. Preclinical results do not predict human outcomes. No human clinical trial data for KPV have been published.

4.2 Animal Colitis and Inflammation Models

Rodent models of intestinal inflammation represent the most developed animal-level evidence for KPV. In dextran sulfate sodium (DSS)-induced and trinitrobenzene sulfonic acid (TNBS)-induced colitis models, systemic or locally delivered KPV has been associated with attenuated disease activity indices, reduced colon shortening, lower histological inflammation scores, and preservation of intestinal architecture compared to vehicle-treated controls [3]. Additional animal studies have examined KPV in models of neuroinflammation and skin inflammation, where anti-inflammatory outcomes consistent with the in vitro literature have been reported. The consistency of anti-inflammatory effects across multiple rodent inflammation models from independent research groups strengthens the mechanistic plausibility of KPV’s proposed activity.

Fig. 1 — Evidence Landscape by Research Stage

Schematic representation of evidence depth at each research stage. Bar lengths are qualitative. In vitro evidence for KPV is among the stronger in this research catalog, with multi-group replication. Animal and human evidence remain limited.

4.3 Nanoparticle and Delivery Research

A notable subset of KPV research has focused on formulation strategies for oral or mucosal delivery to inflamed colonic tissue, addressing KPV’s susceptibility to rapid proteolytic degradation in the gastrointestinal lumen. Nanoparticle encapsulation, hydrogel matrices, and polymer conjugation systems have been developed and tested in rodent colitis models, with reports of improved colonic KPV delivery and enhanced anti-inflammatory efficacy relative to unprotected peptide [4]. This delivery-focused research reflects both the scientific interest in KPV’s anti-inflammatory potential and the practical challenges of peptide bioavailability — a challenge shared with most small research peptides.

4.4 Published Human Data

Despite more than two decades of experimental interest, KPV has not progressed to a controlled human efficacy literature. No peer-reviewed, randomized controlled trial of KPV has been published in human subjects for any inflammatory indication. Human-relevant data in the KPV literature are limited to pharmacological mechanistic studies examining KPV’s receptor binding properties in human cell preparations and to the broader clinical context established for full-length α-MSH and its longer analogs in inflammatory disease [5]. The absence of human clinical trial data means no assessment of KPV’s safety, tolerability, dose-response, or efficacy in human inflammatory disease can be drawn from the published literature.

5. Evidence Status

Table 2 — KPV Evidence Hierarchy by Claim
Proposed Effect	Current Status	Evidence Level
NF-κB inhibition in vitro	Replicated across multiple independent laboratories and cell types	Moderate
Pro-inflammatory cytokine suppression (in vitro)	Consistent reductions in TNF-α, IL-6, IL-1β reported across labs	Moderate
Anti-inflammatory effects in rodent colitis models	Multiple animal studies from independent groups; preclinical only	Limited
MC1R binding and receptor-mediated mechanism	Lower affinity than full α-MSH; receptor vs. non-receptor mechanism not resolved	Limited
Intestinal epithelial barrier protection	In vitro and animal colitis data; no human gut permeability studies	Limited
Human inflammatory disease outcomes	No controlled trials published; no RCT data	Not Established
Human pharmacokinetics / bioavailability	Not characterized; rapid proteolysis expected without protective formulation	Not Established

What We Still Don’t Know

Whether the primary mechanism is MC1R-mediated or receptor-independent: KPV suppresses NF-κB and cytokine production in multiple cell systems, but the upstream molecular event linking KPV to NF-κB inhibition has not been definitively resolved. Whether MC1R engagement, a direct intracellular mechanism, or another route is responsible differs across experimental contexts and has not been unified in a single mechanistic model.
Whether rodent colitis model results translate to human IBD: DSS and TNBS colitis models in mice and rats differ from human Crohn’s disease and ulcerative colitis in etiology, chronicity, immune cell composition, and the comorbidity burden typical of human IBD patients. The predictive value of these models for human clinical outcomes is uncertain.
KPV bioavailability and plasma stability in humans: As an unmodified tripeptide, KPV is expected to be rapidly degraded by plasma and gut peptidases following administration. Whether protective formulation strategies (nanoparticles, PEGylation, D-amino acid substitution) can achieve therapeutically relevant mucosal concentrations of intact KPV in humans has not been established in clinical studies.
Effective dose range in any human context: The preclinical dose-response relationship for KPV has been characterized in animal models, but human dose extrapolation from rodent data for peptide anti-inflammatory agents is unreliable, and no Phase I pharmacokinetic/pharmacodynamic studies for KPV in humans have been published.
Whether NF-κB inhibition extends to non-gut tissue contexts: The large majority of KPV research has been conducted in gut epithelial and intestinal immune contexts. Its proposed anti-inflammatory mechanism involves a ubiquitous signaling pathway, but whether KPV produces meaningful NF-κB suppression in other tissue environments — such as connective tissue, skin, or CNS — at accessible concentrations has not been systematically characterized by independent groups.

6. Limitations of Current Research

Exclusively Preclinical Evidence Despite a relatively broader in vitro evidence base compared to some research peptides, all KPV research remains preclinical. No randomized, placebo-controlled clinical trial of KPV has been published in human subjects for any inflammatory indication, including inflammatory bowel disease — the context in which most animal studies have been conducted. The absence of human trial data means no efficacy, safety, dose-response, or pharmacokinetic claims can be made for human applications.

Evidence Concentrated in Gut Epithelial Models The large majority of KPV preclinical research has been conducted in intestinal epithelial cells, macrophage cultures, and rodent colitis models. Extrapolation of KPV’s proposed NF-κB mechanism to other tissue contexts — such as musculoskeletal, dermal, or CNS inflammation — assumes that the same pathway operates with equivalent sensitivity across tissue types, an assumption that has not been systematically tested in KPV studies.

Substantially Lower MC1R Affinity Than Full α-MSH KPV’s receptor binding affinity for MC1R is much lower than that of the full 13-residue α-MSH sequence, the naturally N-terminally acetylated and C-terminally amidated native peptide. The N-terminal acetyl group and C-terminal amide of α-MSH contribute substantially to receptor binding affinity and metabolic stability. Without these modifications, KPV’s capacity to engage MC1R at physiologically relevant concentrations is reduced, and the extent to which its observed anti-inflammatory effects are MC1R-mediated versus operating through alternative intracellular mechanisms is unclear.

Proteolytic Instability of the Unmodified Tripeptide As an unmodified tripeptide without D-amino acid substitution, N-methylation, or other stability-enhancing modifications, KPV is susceptible to rapid degradation by plasma and tissue peptidases. Aminopeptidases, dipeptidyl peptidases, and carboxypeptidases present in blood, gut lumen, and tissue will rapidly cleave KPV. The half-life of unmodified KPV in plasma has not been characterized in published human studies, and this instability represents a fundamental pharmacokinetic challenge for any route of administration.

Oral and Systemic Bioavailability Not Established Oral bioavailability of unprotected KPV is expected to be negligible due to gut luminal proteolysis and poor transcellular transport of charged tripeptides across the intestinal epithelium. Delivery research using nanoparticle and polymer encapsulation has shown promise in rodent colitis models, but no human pharmacokinetic study has established that any KPV delivery formulation achieves mucosal tissue concentrations of intact peptide sufficient to produce the observed preclinical anti-inflammatory effects.

Rodent Colitis Models Have Limited Predictive Value for Human IBD DSS-induced and TNBS-induced colitis in mice and rats are extensively used screening models but differ from human inflammatory bowel disease in mechanism, immune cell contribution, disease chronicity, and response to known therapies. Multiple compounds that showed efficacy in these rodent models have failed in human IBD trials. The predictive value of positive KPV findings in rodent colitis for clinical outcomes in Crohn’s disease or ulcerative colitis should be interpreted cautiously.

⚠ Research and Informational Use Only. All content on this page is for informational and educational purposes and is intended for qualified research professionals. Nothing on this page constitutes medical advice, diagnosis, or treatment guidance. KPV is supplied by Wholesale Peps as lyophilized powder for in vitro laboratory research only and is not approved by the FDA for human or veterinary use. No regulatory approval has been granted for KPV in any jurisdiction. Read full disclaimer →

References

Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. “Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.” Endocrine Reviews. 2008;29(5):581–602. doi:10.1210/er.2007-0027
Catania A, Gatti S, Colombo G, Lipton JM. “Targeting melanocortin receptors as a novel strategy to control inflammation.” Pharmacological Reviews. 2004;56(1):1–29. doi:10.1124/pr.56.1.1
Getting SJ. “Targeting melanocortin receptors as potential novel anti-inflammatory therapeutics.” Pharmacology & Therapeutics. 2006;111(1):1–15. doi:10.1016/j.pharmthera.2005.06.002
Rajora N, Ceriani G, Catania A, Star RA, Murphy MT, Lipton JM. “Alpha-MSH production, receptors, and influence on neopterin in a human monocyte/macrophage cell line.” Journal of Leukocyte Biology. 1996;59(2):248–253. doi:10.1002/jlb.59.2.248
Luger TA, Brzoska T. “Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.” Annals of the Rheumatic Diseases. 2007;66 Suppl 3:iii52–55. doi:10.1136/ard.2007.078998